Motilal Oswal's research report on Apollo Hospitals
Apollo Hospital and Enterprise (AHEL) delivered better-than-expected 2QFY25 on account of improved occupancy and reduced operating costs at Healthco. The performance was partly impacted by reduced patient flow from Bangladesh due to ongoing political issues. The higher medical mix compared to the surgical mix led to moderate YoY growth in ARPOB for the quarter. We raise our earnings estimate by 9%/3%/3% for FY25/FY26/FY27 to factor in: a) reduced marketing cost driving better profitability in Healthco, b) increased patient flow in the hospital business driving better operating leverage, and c) additional business from insurance products/concierge services in Healthco.
Outlook
We value AHEL on an SOTP basis (34x EV/EBITDA for hospital business, 15x EV/EBITDA for retained pharmacy, 22x EV/EBITDA for front-end pharmacy, 15x EV/EBITDA for retained pharmacy, and 2x EV/sales for Apollo 24/7) to arrive at a TP of INR8,660.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.